Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...

Multiple studies have demonstrated people with established schizophrenia have an increased dopamine synthesis capacity, and ...

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it ...

Antipsychotics are the best defense against relapse in schizophrenia, even though that protection often comes at the expense ...

Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push.  | Bristol Myers' $1.5 billion restructuring initiative that ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 ...

Drone systems gain further momentum, signaling a shift in modern warfare tactics. U.S. battery manufacturing supply chain ...

people lost a few pounds while taking Cobenfy, made by Bristol Myers Squibb. Dr. John Krystal of Yale University has led research on other schizophrenia drugs but was not involved in the new ...